Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments

SIMPLE SUMMARY: The treatment of high-risk neuroblastoma patients with anti-GD2 antibodies has improved survival, and it is an established treatment strategy; however, many patients still experience a late relapse. One disadvantage of passive immunotherapy is the absence of a memory response. Theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Klingel, Leah, Siebert, Nikolai, Troschke-Meurer, Sascha, Zumpe, Maxi, Ehlert, Karoline, Huber, Stefanie, Loibner, Hans, Mutschlechner, Oliver, Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735439/
https://www.ncbi.nlm.nih.gov/pubmed/36497290
http://dx.doi.org/10.3390/cancers14235802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735439/
https://www.ncbi.nlm.nih.gov/pubmed/36497290
http://dx.doi.org/10.3390/cancers14235802

Ejemplares similares